J. Harousseau

P. Moreau, T. Facon, J. Harousseau, 2011, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.

K. Anderson, H. Einsele, P. Sonneveld, 2009, Blood.

bortezomib- containing regimens cell collection following initial therapy with thalidomide, lenalidomide or Mobilization in myeloma revisited: IMWG consensus perspectives on stem

K. Anderson, H. Einsele, P. Sonneveld, 2009 .

Hematopoietic stem cell transplantation in multiple myeloma.

J. Harousseau, 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

Thalidomide as maintenance therapy after autologous stem-cell transplantation

J. Harousseau, 2009 .

Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.

P. Moreau, H. Avet-Loiseau, G. Marit, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Integrating Novel Therapies in the Transplant Paradigm

J. Harousseau, 2009, Cancer journal.

Individualizing treatment of patients with myeloma in the era of novel agents.

K. Anderson, J. Harousseau, J. San-Miguel, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Induction therapy in multiple myeloma.

J. Harousseau, 2008, Hematology. American Society of Hematology. Education Program.

The evolving background for high-dose treatment for myeloma

K. Anderson, B. Sirohi, J. Harousseau, 2007, Bone Marrow Transplantation.

Stem cell transplantation in multiple myeloma.

P. Moreau, H. Avet-Loiseau, J. Harousseau, 2007, Hematology. American Society of Hematology. Education Program.

Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials

B. Grosbois, I. Yakoub-Agha, M. Mohty, 2007, Leukemia.

Role of autologous stem-cell transplantation in multiple myeloma.

J. Harousseau, M. Attal, 2007, Best practice & research. Clinical haematology.

The allogeneic dilemma

J. Harousseau, 2007, Bone Marrow Transplantation.

Role of stem cell transplantation.

J. Harousseau, 2007, Hematology/oncology clinics of North America.

Role of bone marrow transplantation in the disease pathway of myeloma.

P. Moreau, J. Harousseau, 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

A Comprehensive Analysis of Cytogenetic Abnormalities in Myeloma: Results of the FISH Analysis of 1000 Patients Enrolled in the IFM99 Trials.

P. Moreau, C. Mathiot, T. Facon, 2005 .

Multiple Myeloma Treatment in Real‐world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

Jesús Martín Sánchez, M. Beksac, H. Goldschmidt, 2018, Clinical lymphoma, myeloma & leukemia.

Stage I-IIE primary non-Hodgkin's lymphoma of the testis: results of a prospective trial by the GOELAMS Study Group.

P. Colombat, J. Harousseau, C. Linassier, 2002, Clinical lymphoma.

randomized study in adult de novo acute myelogenous leukemia Quinine as a multidrug resistance inhibitor: a phase 3 multicentric

E. Solary, M. Bernard, B. Drénou, 2013 .

Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia.

E. Solary, M. Bernard, B. Drénou, 2003, Blood.

High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma.

D. Huglo, M. Pfreundschuh, L. Trümper, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prior treatment with gemtuzumab ozogamicin and the risk of veno-occlusive disease after allogeneic haematopoietic stem cell transplantation

P. Chevallier, D. Blaise, M. Mohty, 2010, Bone Marrow Transplantation.

Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.

P. Chevallier, P. Moreau, H. Avet-Loiseau, 2005, Leukemia research.

Re-administration of a combination of chemotherapy + Gemtuzumab at relapse in CD33+ AML patient allows to second remission and is feasible without extra toxicity.

P. Chevallier, C. Touzeau, J. Delaunay, 2008, Leukemia research.

Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.

P. Chevallier, M. Mohty, H. Avet-Loiseau, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression

P. Chevallier, J. Delaunay, B. Mahé, 2008, International journal of hematology.

Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate-dose cytarabine.

J. Reiffers, P. Hurteloup, N. Ifrah, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Addition of Gemtuzumab Ozogamycin to Chemotherapy Improves Event-Free Survival but Not Overall Survival of AML Patients with Intermediate Cytogenetics Not Eligible for Allogeneic Transplantation. Results of the GOELAMS AML 2006 IR Study

C. Volteau, M. Béné, C. Récher, 2011 .

Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial.

M. Béné, N. Ifrah, J. Harousseau, 2004, Blood.

Surgical treatment of a foscavir-resistant atypical Cytomegalovirus pneumonia in an allogeneic stem cell transplant recipient

P. Chevallier, D. Boutolleau, P. Moreau, 2008, Haematologica.

Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS.

R. Houot, L. Fornecker, R. Gressin, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma

P. Moreau, H. Avet-Loiseau, J. Harousseau, 2016, Haematologica.

Therapeutic advances in the treatment of primary plasma cell leukemia: a focus on hematopoietic cell transplantation.

J. Harousseau, M. Kharfan-Dabaja, R. Baz, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.

J. Shaughnessy, M. Dimopoulos, P. Sonneveld, 2011, Blood.

Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.

B. Barlogie, M. Dimopoulos, A. Palumbo, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Plasma cell growth fraction using Ki‐67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I

I. Yakoub-Agha, A. Duhamel, F. Bauters, 2007, European journal of haematology.

LEADING ARTICLE International uniform response criteria for multiple myeloma

M. Beksac, B. Barlogie, G. Morgan, 2006 .

Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte.

H. Tilly, N. Brousse, C. Sebban, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation

A. Zander, C. Crawley, J. Passweg, 2008, Haematologica.

Reactive plasmacytoses can mimick plasma cell leukemia: Therapeutical implications

R. Bataille, C. Pellat-deceunynck, P. Moreau, 2007, Leukemia & lymphoma.

The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma

R. Bataille, M. Amiot, C. Pellat-deceunynck, 1998, Leukemia.

Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myélome.

R. Bataille, B. Grosbois, H. Avet-Loiseau, 1999, Blood.

High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies.

R. Bataille, Jian-yong Li, T. Facon, 1998, Cancer research.

Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study.

G. Salles, P. Moreau, X. Leleu, 2009, Blood.

High-dose melphalan and autologous bone marrow transplantation for systemic AL amyloidosis with cardiac involvement.

R. Bataille, P. Moreau, J. Harousseau, 1996, Blood.

Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy

R. Bataille, M. Amiot, C. Pellat-deceunynck, 1999, Leukemia.

Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy.

R. Bataille, P. Moreau, H. Avet-Loiseau, 2002, Blood.

CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma.

R. Bataille, P. Moreau, H. Avet-Loiseau, 2003, Blood.

Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants.

R. Bataille, H. Avet-Loiseau, J. Harousseau, 2003, Blood.

H. Tilly, B. Quesnel, E. Archimbaud, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

R. Berger, R. Berger, M. Sanz, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).

P. Moreau, S. Minvielle, H. Avet-Loiseau, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials

P. Sonneveld, S. Jagannath, P. Richardson, 2007, Leukemia.

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

D. Esseltine, H. van de Velde, P. Moreau, 2011, The Lancet. Oncology.

Comparison of Intensive Chemotherapy and Autologous Transplantation as Post Remission Therapy in Adult Acute Myeloid Leukemia. Update of the GOELAM 1 Trial

J. Harousseau, J. Cahn, M. Chevalier, 2001 .

Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques.

E. Solary, E. Deconinck, O. Tournilhac, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma: A phase I/II study.

S. Jagannath, S. Lonial, R. Vij, 2010 .

Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantion (ASCT) in previously untreated multiple myeloma (MM): Updated data from IFM 2005/01 trial

P. Moreau, H. Avet-Loiseau, G. Marit, 2008 .

Mitoxantrone/Cytarabine with or without Quinine as a Potential MDR- Reversing Agent for the Treatment of Acute Leukemias

E. Solary, P. Moreau, N. Ifrah, 1996 .

How Treat How I treat ﬁ rst relapse of myeloma

J. Harousseau, M. Attal, 2017 .

How I treat first relapse of myeloma.

J. Harousseau, M. Attal, 2017, Blood.

A pivotal role for Mcl-1 in Bortezomib-induced apoptosis

M. Amiot, J. Opferman, Jing Zhang, 2008, Oncogene.

Randomized Clinical Trial Comparing Melphalan-Prednisone (MP), MP-Thalidomide (MP-THAL) and High-Dose Therapy Using Melphalan 100 MG/M2 (MEL100) for Newly Diagnosed Myeloma Patients Aged 65–75 Years. Interim Analysis of the IFM 99-06 Trial on 350 Patients.

B. Pégourié, J. Mary, G. Guillerm, 2004 .

Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas.

C. Gisselbrecht, P. Borchmann, J. Harousseau, 2003, Haematologica.

Pharmacokinetics of idarubicin after daily intravenous administration in leukemic patients.

J. Reiffers, J. Robert, P. Hurteloup, 1987, Leukemia research.

P53 deletion is not a frequent event in multiple myeloma

R. Bataille, Jian-yong Li, H. Avet-Loiseau, 1999, British journal of haematology.

ACUTE LYMPHOBLASTIC LEUKEMIA ASSOCIATED WITH DERMATOMYOSITIS IN A CHILD

J. Harousseau, J. Stalder, F. Millot, 1993, Pediatric dermatology.

Patient and Caregiver Experience Decision Factors in Treatment Decision Making-Results of a Systematic Literature Review of Multiple Myeloma Decision Aids.

D. Hose, P. Keown, J. Harousseau, 2022, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

N. Munshi, P. Richardson, P. Moreau, 2017, The New England journal of medicine.

NK-KIR transcript kinetics correlate with acute graft-versus-host disease occurrence after allogeneic bone marrow transplantation.

M. Bonneville, J. Harousseau, K. Gagne, 2005, Human immunology.

[Leukemias induced by anticancer chemotherapies].

J. Harousseau, 1999, Bulletin du cancer.

Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression

P. Sonneveld, R. Orlowski, J. Harousseau, 2011, Cancer.

Efficacy and outcome of autologous transplantation in rare myelomas

H. Goldschmidt, G. Morgan, S. Iacobelli, 2009, Haematologica.

Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study

R. Neuwirth, D. Esseltine, H. Goldschmidt, 2008, Leukemia.

Safety and efficacy of bortezomib in high‐risk and elderly patients with relapsed multiple myeloma

P. Sonneveld, S. Lonial, P. Richardson, 2007, British journal of haematology.

Late Complications and Quality of Life after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation.

P. Chevallier, M. Mohty, P. Moreau, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Features of EBV reactivation after reduced intensity conditioning unrelated umbilical cord blood transplantation

P. Chevallier, M. Mohty, P. Moreau, 2012, Bone Marrow Transplantation.

Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation.

N. Schmitz, C. Kyriakou, G. Kobbe, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunoglobulins D and M multiple myeloma variants are heavily mutated.

R. Bataille, C. Heirman, K. Thielemans, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma.

J. Bourhis, V. Leblond, G. Marit, 1995, Stem cells.

COST-EFFECTIVENESS OF TREATMENTS FOR MILD-TO-MODERATE OBSTRUCTIVE SLEEP APNEA IN FRANCE

J. Harousseau, L. Perrier, H. Späth, 2016, International Journal of Technology Assessment in Health Care.

Is ASCT With TBI Superior to ASCT Without TBI in Mantle Cell Lymphoma Patients?

P. Chevallier, M. Mohty, P. Moreau, 2012, Transplantation.

A phase I study of pixantrone (BBR 2778) in combination with cyclophosphamide, vincristine and prednisone in patients with relapsed aggressive non-Hodgkin's lymphoma.

P. Borchmann, J. Harousseau, R. Herbrecht, 2003 .

Tandem high-dose therapy followed by autologous stem-cell transplantation for refractory or relapsed high grade non-Hodgkin's lymphoma with poor prognosis factors: a prospective pilot study.

P. Moreau, J. Harousseau, N. Milpied, 2002, Haematologica.

Minimal Residual Disease Negativity Is a New End Point of Myeloma Therapy.

H. Avet-Loiseau, J. Harousseau, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers

M. Mohty, J. Harousseau, 2014, Haematologica.

Evolving role of stem cell transplantation in multiple myeloma.

P. Moreau, J. Harousseau, 2005, Clinical lymphoma & myeloma.

Dose-Intensive Therapy With Autologous Stem Cell Transplantation for Patients With Multiple Myeloma

G. Schiller, J. Harousseau, M. Attal, 2004 .

Traitement intensif du myélome multiple

J. Harousseau, 2003 .

The role of stem cell transplantation in multiple myeloma.

J. Harousseau, M. Attal, 2002, Blood reviews.

High-dose therapy in multiple myeloma.

J. Harousseau, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

High dose chemotherapy and autologous bone marrow transplantation in refractory Hodgkin's disease.

P. Hervé, J. Harousseau, T. Philip, 1986, British Journal of Cancer.

Running head: TIPIFARNIB IN REFRACTORY OR RELAPSED AML

J. Reiffers, J. Lancet, X. Thomas, 2007 .

Analysis of platelet recovery after autologous transplantation with G-CSF mobilized CD34+ cells purified from leukapheresis products.

R. Bataille, S. Hermouet, B. Mahé, 1997, Hematology and cell therapy.

Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalities.

M. Béné, C. Récher, N. Ifrah, 2011, Blood.

VELCADE/Dexamethasone (Vel/Dex) Versus VAD as Induction Treatment Prior to Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM): An Interim Analysis of the IFM 2005-01 Randomized Multicenter Phase III Trial.

D. Esseltine, M. Mohty, G. Marit, 2006 .

Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients--a study of the groupe d'Etude des lymphomes de l'Adulte.

B. Coiffier, H. Tilly, N. Brousse, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Placebo-Controlled Study of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor Administered During and After Induction Treatment for De Novo Acute Myelogenous Leukemia in Elderly Patients

P. Hurteloup, J. Harousseau, Z. Tellier, 1998 .

Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study.

P. Chevallier, D. Blaise, M. Béné, 2012, Blood.

Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma.

P. Moreau, W. Bezwoda, P. Colombat, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Standard therapy versus autologous transplantation in multiple myeloma.

J. Harousseau, M. Attal, J. Harousseau, 1997, Hematology/oncology clinics of North America.

A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia.

Bob Löwenberg, Jason Gotlib, Yixin Wang, 2007, Blood.

Genotypically nonidentical related donors for transplantation of patients with myelodysplastic syndromes: comparison with unrelated donor transplantation and autologous stem cell transplantation

A. Gratwohl, D. Niederwieser, J. Hermans, 2001, Leukemia.

A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).

P. Hurteloup, J. Harousseau, Z. Tellier, 1998, Blood.

Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.

R. Bataille, M. Amiot, B. Monia, 2002, Blood.

Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization.

R. Bataille, Jian-yong Li, A. Moreau, 1999, The American journal of pathology.

Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation

P. Chevallier, M. Mohty, P. Moreau, 2011, Leukemia.

Maintenance Treatment with Lenalidomide After Transplantation for MYELOMA: Final Analysis of the IFM 2005-02.

P. Moreau, H. Avet-Loiseau, G. Marit, 2010 .

A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study

M. Labopin, P. Chevallier, M. Mohty, 2011, Leukemia.

Allogeneic hematopoietic stem-cell transplantation for myeloid sarcoma: a retrospective study from the SFGM-TC.

C. Volteau, P. Chevallier, D. Blaise, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.

W. Jędrzejczak, H. Dombret, G. Martinelli, 2007, Blood.

When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group).

H. Dombret, A. Baruchel, S. Chevret, 2009, Leukemia research.

The Role of Colony-Stimulating Factors in the Treatment of Acute Leukaemia

J. Harousseau, 1997, BioDrugs.

Granulocyte-Macrophage Colony-Stimulating Factor During and After Remission Induction Treatment for Elderly Patients with Acute Myeloid Leukemia

C. Gardin, P. Hurteloup, N. Ifrah, 1997 .

The use of GM-CSF and G-CSF in the treatment of acute leukemias.

J. Harousseau, D. Wu, D. Wu, 1995, Leukemia & lymphoma.

Phase I Study of AVE1642 Anti IGF-1R Monoclonal Antibody in Patients with Advanced Multiple Myeloma.

M. Boccadoro, P. Moreau, T. Facon, 2007 .

Detection of t(11;14) using interphase molecular cytogenetics in mantle cell lymphoma and atypical chronic lymphocytic leukemia

M. Batzer, R. Bataille, H. Avet-Loiseau, 1998, Genes, chromosomes & cancer.

High dose radiochemotherapy followed by autologous stem cell transplantation in four patients with multiple lymphomatous polyposis

P. Moreau, A. Moreau, B. Mahé, 1995, Cancer.

Outcome of adult T-lymphoblastic lymphoma after acute lymphoblastic leukemia-type treatment: a GOELAMS trial

M. Béné, N. Ifrah, J. Harousseau, 2007, Haematologica.

High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma.

P. Moreau, J. Harousseau, N. Milpied, 2005, Haematologica.

Bortezomib Plus Dexamethasone (VD)Versus Reduced-dose bortezomib Plus Thalidomide Plus Dexametasone (vTD) as Induction Treatment Prior to Autologous Stem-Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM)

J. Mary, P. Moreau, H. Avet-Loiseau, 2009 .

TREATMENT OF ESSENTIAL THROMBOCYTHAEMIA BY ALPHA 2a INTERFERON

J. Harousseau, P. Brice, G. Tobelem, 1988, The Lancet.

Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin.

P. Chevallier, H. Avet-Loiseau, J. Harousseau, 2002, Cancer research.

Ploidy, as Detected by Fluorescence In Situ Hybridization, Defines Different Subgroups in Multiple Myeloma.

F. Magrangeas, S. Minvielle, H. Avet-Loiseau, 2004 .

Induction with Velcade®/Dexamethasone Partially Overcomes the Poor Prognosis of t(4;14), but Not That of Del(17p), in Young Patients with Multiple Myeloma.

P. Moreau, S. Minvielle, G. Marit, 2009 .

Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation.

P. Chevallier, M. Mohty, P. Moreau, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

What is the impact of accreditation recommendations on healthcare organisations ? A pilot study of accreditation data Summary Division for the improvement of quality and safety of care

J. Harousseau, J. Guérin, 2013 .

Stem-cell transplantation in multiple myeloma.

P. Moreau, H. Avet-Loiseau, T. Facon, 2005, Best practice & research. Clinical haematology.

Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial.

A. Grañena, J. Reiffers, R. Schots, 1999, Blood.

Optimizing peripheral blood progenitor cell autologous transplantation in multiple myeloma.

J. Harousseau, 1999, Haematologica.

Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma

T. Soussi, P. Moreau, F. Magrangeas, 2010, Haematologica.

(IFM) myeloma: a phase 2 study of the Intergroupe Francophone du Myélome autologous stem cell transplantation in patients with de novo multiple Bortezomib and high-dose melphalan as conditioning regimen before

B. Pégourié, J. Mary, P. Moreau, 2013 .

Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).

B. Pégourié, J. Mary, P. Moreau, 2010, Blood.

Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.

R. Neuwirth, H. Goldschmidt, P. Sonneveld, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bortezomib in multiple myeloma: treatment approach and outcomes

J. Harousseau, 2004 .

Relapsed refractory multiple myeloma: a comprehensive overview

M. Mohty, J. Harousseau, F. Malard, 2019, Leukemia.

Long-term results of total abdominopelvic irradiation in non-Hodgkin's lymphomas after failure of chemotherapy.

P. Moreau, A. Moreau, M. Mahé, 1998, International journal of radiation oncology, biology, physics.

Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment.

P. Sonneveld, A. Nagler, R. Hájek, 2008, Clinical lymphoma & myeloma.

Assessment of caspase activity as a possible prognostic factor in acute myeloid leukaemia

L. Oliver, F. Vallette, B. Mahé, 2002, British journal of haematology.

Lenalidomide maintenance after transplantation for myeloma.

P. Moreau, H. Avet-Loiseau, G. Marit, 2010 .

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.

B. Pégourié, O. Decaux, C. Sebban, 2011, Blood.

Itraconazole Oral Solution for Primary Prophylaxis of Fungal Infections in Patients with Hematological Malignancy and Profound Neutropenia: a Randomized, Double-Blind, Double-Placebo, Multicenter Trial Comparing Itraconazole and Amphotericin B

J. Harousseau, M. Peeters, A. Fassas, 2000, Antimicrobial Agents and Chemotherapy.

Mcl‐1 and Bcl‐xL are co‐regulated by IL‐6 in human myeloma cells

R. Bataille, M. Amiot, D. Puthier, 1999, British journal of haematology.

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.

T. Willis, B. Pégourié, P. Richardson, 2018, Blood.

Treatment of transplant-eligible patients

M. Mohty, J. Harousseau, F. Malard, 2015 .

myeloma autologous stem cell transplantation in newly diagnosed multiple thalidomide plus dexamethasone as induction treatment before Bortezomib plus dexamethasone versus reduced-dose bortezomib,

O. Decaux, C. Sebban, P. Moreau, 2012 .

Continuous reduced nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a single-institution's three decade experience.

P. Chevallier, M. Mohty, P. Moreau, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phenotype of Normal and Malignant Pc: Universal Pc Marker, Markers Associated with Malignancy, Markers of Severity a Universal Marker of Normal and Malignant Plasma Cells: Cd138 (syndecan-1)

R. Bataille, M. Amiot, C. Pellat-deceunynck, 2006 .

Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization.

R. Bataille, M. Amiot, C. Pellat-deceunynck, 1995, Cancer research.

Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma

Michael L. Wang, M. Dimopoulos, J. Zeldis, 2010, Haematologica.

Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required.

P. Chevallier, P. Moreau, B. Mahé, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Viridans streptococcal bacteraemia in patients with neutropenia

P. Moreau, H. Richet, J. Harousseau, 1995, The Lancet.

Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases

P. Chevallier, M. Mohty, H. Avet-Loiseau, 2009, Leukemia.

Autologous stem cell transplantation

J. Harousseau, M. Attal, 2004 .

Hematopoietic cell transplantation in multiple myeloma

P. Moreau, J. Harousseau, 2004 .

Randomized trial experience of the Intergroupe Francophone du Myélome.

J. Harousseau, M. Attal, 2001, Seminars in hematology.

Initial fluconazole prophylaxis may not be required in adults with acute leukemia or myelodysplastic/myeloproliferative disorders after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation

P. Chevallier, M. Mohty, M. Béné, 2015, Annals of Hematology.

A Phase II Study of Oral Panobinostat (LBH589) in Adult Patients with Advanced Refractory Multiple Myeloma

H. Goldschmidt, S. Lonial, R. Vij, 2008 .

Effect of the combination of pegylated liposomal doxorubicin and bortezomib on time to progression (TTP) and overall survival of patients with relapsed/refractory multiple myeloma compared with bortezomib alone

P. Sonneveld, A. Nagler, R. Hájek, 2007 .

Fractionated radioimmunotherapy in NHL with DOTA-conjugated, humanized anti-CD22 IgG, epratuzumab: Results at high cumulative doses of 90Y

D. Huglo, F. Kraeber-Bodéré, J. Chatal, 2008 .

Oral Idarubicin and Low Dose Cytarabine as the Initial Treatment of Acute Myeloid Elderly Patients in Leukemia

J. Reiffers, P. Hurteloup, P. Collombat, 1991 .

The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma

D. Esseltine, P. Sonneveld, P. Richardson, 2008, British journal of haematology.

Retrospective evaluation of autologous bone marrow transplantation vs allogeneic bone marrow transplantation from an HLA identical related donor in acute myelocytic leukemia. A study of the European Cooperative Group for Blood and Marrow Transplantation (EBMT).

M. Labopin, G. Meloni, J. Reiffers, 1996, Bone marrow transplantation.

Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation.

G. Morgan, J. San Miguel, P. Sonneveld, 2003, The hematology journal : the official journal of the European Haematology Association.

Salvage extended-field irradiation in follicular non-Hodgkin's lymphoma after failure of chemotherapy.

P. Moreau, A. Moreau, M. Mahé, 2000, International journal of radiation oncology, biology, physics.

High Complete and Very Good Partial Response Rates with Bortezomib—Dexamethasone as Induction Prior to ASCT in Newly Diagnosed Patients with High-Risk Myeloma: Results of the IFM2005-01 Phase 3 Trial.

P. Moreau, H. Avet-Loiseau, G. Marit, 2009 .

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

M. Dimopoulos, J. San Miguel, S. Jagannath, 2011, Blood.

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.

H. Goldschmidt, U. Mellqvist, M. Dimopoulos, 2021, The Lancet. Oncology.

Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma

P. Moreau, X. Leleu, J. Harousseau, 2008, Haematologica.

Pharmacokinetics of Itraconazole Oral Solution in Neutropenic Children during Long-Term Prophylaxis

J. Levron, S. Lemerle, J. Harousseau, 2001, Antimicrobial Agents and Chemotherapy.

Systematic literature review of health economic models developed for multiple myeloma to support future analyses.

D. Hose, P. Keown, J. Harousseau, 2022, Journal of medical economics.

Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells.

R. Bataille, M. Amiot, C. Pellat-deceunynck, 2006, Blood.

Hematologic Profiles in the Phase 3 APEX Trial.

H. Goldschmidt, P. Sonneveld, S. Lonial, 2005 .

[Thrombotic manifestations and acute distal ischemia in primary antiphospholipid syndrome in children].

A. Prieur, J. Harousseau, J. Sizun, 1992, Archives francaises de pediatrie.

Blockade of p110delta isoform activity of phosphoinositide 3-kinase inhibits blast cell proliferation in acute myeloblastic leukemia.

E. Solary, B. Vanhaesebroeck, M. Béné, 2004 .

Use of Recombinant Interleukin-2 (RU 49637) After Autologous Bone Marrow Transplantation in Patients with Hematological Disease: Phase I–II Study

D. Olive, D. Blaise, J. Reiffers, 1992 .

Multiple myeloma in the elderly: when to treat, when to go to transplant.

J. Harousseau, 2010, Oncology.

Phase 2 Study of 2 Modalities of Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. IFM 2009-02

B. Pégourié, A. Duhamel, P. Moreau, 2010 .

Comparison of reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): Results of IFM2007-02 study.

P. Moreau, H. Avet-Loiseau, G. Marit, 2010 .

The role of autologous hematopoietic stem cell transplantation in multiple myeloma.

J. Harousseau, M. Attal, 1997, Seminars in hematology.

Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma.

J. Bourhis, V. Leblond, G. Marit, 1995, Bone marrow transplantation.

Interferon Alpha and Cytosine Arabinoside in the Treatment of Chronic Myelogenous Leukemia

R. Bouabdallah, F. Bauters, N. Ifrah, 1998 .

Treatment of Philadelphia Chromosome Positive ALL with Interferon Alpha

J. Harousseau, F. Guilhot, P. Casassus, 1996 .

A multicentric randomised study of alpha 2b interferon (IFN) and hydroxyurea (HU) with or without cytosine-arabinoside (Ara-c) in previously untreated patients with Ph+ chronic myelocytic leukemia (CML): preliminary cytogenetic results.

H. Tilly, F. Bauters, N. Ifrah, 1993, Leukemia & lymphoma.

report of the International Myeloma Workshop Consensus Panel 2 Consensus recommendations for risk stratification in multiple myeloma

J. Shaughnessy, M. Dimopoulos, A. Palumbo, 2011 .

Deletions Are Not Primary Events in B-Cell Chronic Lymphocytic Leukemia : A Study of 100 Patients Using Fluorescence in Situ Hybridization 1

Herv, R. Bataille, M. Devilder, 2005 .

13q14 deletions are not primary events in B-cell chronic lymphocytic leukemia: a study of 100 patients using fluorescence in situ hybridization.

R. Bataille, M. Devilder, J. Moisan, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Stem cell transplantation in multiple myeloma (0, 1, or 2)

J. Harousseau, 2005, Current opinion in oncology.

Combined Vorinostat, Lenalidomide and Dexamethasone Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase I Study.

M. Dimopoulos, P. Richardson, C. Mitsiades, 2009 .

[Cost effectiveness of GM-CSF in the treatment of acute myeloblastic leukemia in aged patients: protocol of GOELAM Sa3].

P. Arveux, J. Harousseau, J. Cahn, 2001, Therapie.

HLA-DPB and susceptibility to hodgkins disease

P. Moreau, J. Harousseau, A. Cesbron, 1993 .

TREATMENT OF ACUTE NON-LYMPHOBLASTIC LEUKAEMIA IN ELDERLY PATIENTS

M. Marty, J. Harousseau, N. Milpied, 1984, The Lancet.

Idarubicin in the treatment of relapsed or refractory acute myeloid leukemia.

J. Reiffers, P. Hurteloup, P. Dufour, 1987, Cancer treatment reports.

Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myélome.

R. Bataille, B. Grosbois, Jian-yong Li, 1999, Blood.

Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial)

N. Munshi, P. Richardson, P. Moreau, 2015 .

Low‐dose vs. high‐dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome

B. Pégourié, I. Yakoub-Agha, M. Mohty, 2012, European journal of haematology.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Alessandro Corso, Robin Foà, M. Dimopoulos, 2007, The New England journal of medicine.

[Rare pulmonary mycoses in patients with hematologic diseases].

J. Harousseau, N. Milpied, P. Breton, 1998, Revue de pneumologie clinique.

Disseminated mucormycosis associated with invasive pulmonary aspergillosis in a patient treated for post-transplant high-grade non-Hodgkin's lymphoma

P. Moreau, J. Harousseau, N. Milpied, 2004, Leukemia & lymphoma.

Infectious complications after unrelated umbilical cord blood transplantation in adult patients with hematologic malignancies.

P. Chevallier, M. Mohty, P. Moreau, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Clinical spectrum and long-term follow-up of 14 cases with G6PC3 mutations from the French severe congenital neutropenia registry

C. Picard, M. Frémond, J. Bruneau, 2014, Orphanet Journal of Rare Diseases.

Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS Study.

M. Béné, C. Récher, F. Bauduer, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Salvage high-dose chemotherapy for children with extragonadal germ-cell tumours

G. Dini, I. Yaniv, U. de Giorgi, 2005, British Journal of Cancer.

Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group.

C Chastang, R. Bouabdallah, C. Chastang, 1997, The New England journal of medicine.

Rothmund-Thomson syndrome and osteosarcoma.

H. Avet-Loiseau, J. Harousseau, I. Cumin, 1996, Medical and pediatric oncology.

[Improvement in the control of chemotherapy induced emesis with ondansetron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic treatment and uncontrolled by a previous antiemetic combination].

R. Zittoun, J. Harousseau, M. Hédouin, 2000, Bulletin du cancer.

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial

B. Pégourié, B. Grosbois, I. Yakoub-Agha, 2007, The Lancet.

Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome.

Laurence Lodé, Catherine Charbonnel, Wilfried Gouraud, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.

R. Gressin, E. Deconinck, P. Colombat, 2004, The New England journal of medicine.

False-positive hepatitis C virus antibody tests in paraproteinaemia

B. Planchon, J. Harousseau, J. Muller, 1990, The Lancet.

International uniform response criteria for multiple myeloma

B. Barlogie, G. Morgan, M. Dimopoulos, 2006, Leukemia.

Hb Potomac [β101(G3)Glu→Asp] in a Polish Family Living in France

Y. Blouquit, F. Galactéros, J. Harousseau, 1987 .

High incidence of deletions but infrequent inactivation of the retinoblastoma gene in human myeloma cells

R. Bataille, M. Amiot, J. Harousseau, 1995, British journal of haematology.

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

R. Bataille, B. Grosbois, I. Yakoub-Agha, 2007, Blood.

CD38 expression and secondary 17p deletion are important  prognostic factors in chronic lymphocytic leukaemia

R. Bataille, P. Chevallier, P. Moreau, 2002, British journal of haematology.

Comparative genomic hybridization is a powerful tool, complementary to cytogenetics, to identify chromosomal abnormalities in childhood acute lymphoblastic leukaemia

R. Bataille, J. Harousseau, P. Talmant, 1997, British journal of haematology.

Gamma groceries.

P. Hervé, J. Harousseau, T. Philip, 1998, Environmental health perspectives.

Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group

M. Mohty, P. Moreau, R. Gressin, 2010, European Journal of Nuclear Medicine and Molecular Imaging.

Proteasome inhibitors in multiple myeloma: 10 years later.

Michele Cavo, Philippe Moreau, A. Palumbo, 2012, Blood.

A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma

J. Rossi, R. Bataille, N. Ifrah, 1996 .

Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis.

M. Mohty, J. Harousseau, F. Malard, 2017, Cancer treatment reviews.

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

H. Goldschmidt, M. Dimopoulos, A. Palumbo, 2016, The Lancet. Oncology.

Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement

U. Mellqvist, G. Morgan, H. Einsele, 2011, Leukemia.

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)

B. Barlogie, G. Morgan, M. Dimopoulos, 2009, Leukemia.

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.

J. Rossi, R. Bataille, N. Ifrah, 1996, The New England journal of medicine.

Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival

R. Bataille, M. Amiot, P. Moreau, 2005, Leukemia.

1 VEGF INDUCES MCL-1 UPREGULATION AND PROTECTS MULTIPLE MYELOMA CELLS AGAINST APOPTOSIS

M. Amiot, P. Richardson, Shaji K. Kumar, 2004 .

Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation.

R. Bataille, B. Grosbois, F. Magrangeas, 2002, Blood.

Fluorescence I n S itu H ybridization o n P eripheral-Blood Specimens I s a R eliable M ethod t o E valuate C ytogenetic Response i n C hronic M yeloid L eukemia

P. Moreau, J. Harousseau, P. Talmant, 2000 .

Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease.

R. Bataille, F. Bertucci, B. Loriod, 2003, Blood.

A 5′ splice region G → C mutation in exon 3 of the human β‐spectrin gene leads to decreased levels of β‐spectrin mRNA and is responsible for dominant hereditary spherocytosis (spectrin Guemene‐Penfao)

B. Grandchamp, J. Harousseau, I. Devaux, 1998, British journal of haematology.

Light-chain only multiple myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level.

R. Bataille, G. Descamps, F. Magrangeas, 2004, Blood.

Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors.

R. Bataille, F. Magrangeas, S. Minvielle, 2001, Blood.

Intensive short term therapy with granulocyte‐macrophage–colony stimulating factor support, similar to therapy for acute myeloblastic leukemia, does not improve overall results for adults with acute lymphoblastic leukemia

N. Ifrah, J. Harousseau, C. Linassier, 1999 .

against apoptosis VEGF induces MCL-1 upregulation and protects multiple myeloma cells

M. Amiot, P. Richardson, Shaji K. Kumar, 2013 .

myeloma cells apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated

R. Bataille, M. Amiot, C. Pellat-deceunynck, 2011 .

Mcl-1 Regulation and Its Role in Multiple Myeloma

K. Podar, J. Harousseau, S. Gouill, 2004, Cell cycle.

Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells

R. Bataille, M. Amiot, C. Pellat-deceunynck, 2002, Leukemia.

Prolonged PFS after Autologous Stem Cell Transplantation in Follicular Lymphoma Patients: A Long-Term Retrospective Study.

P. Moreau, L. Planche, B. Mahé, 2008 .

Interleukin-l0 Is a Proliferation Factor But Not a Differentiation Factor for Human Myeloma Cells

B. Klein, R. Bataille, J. Harousseau, 2002 .

14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myélome.

R. Bataille, B. Grosbois, H. Avet-Loiseau, 1999, Cancer research.

High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization

R. Bataille, Jian-yong Li, H. Avet-Loiseau, 1999, Genes, chromosomes & cancer.

Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells.

R. Bataille, M. Amiot, C. Pellat-deceunynck, 1999, Blood.

Ten-year results of a strategy combining three cycles of ABVD and high-dose extended irradiation for treating Hodgkin's disease at advanced stages.

J. Jais, J. Harousseau, F. Guilhot, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Amplification of the 11q23 region in acute myeloid leukemia

R. Bataille, Jian-yong Li, H. Avet-Loiseau, 1999, Genes, chromosomes & cancer.

Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia

E. Solary, B. Vanhaesebroeck, N. Ifrah, 2005 .

Essential role for the p 110 δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia

E. Solary, B. Vanhaesebroeck, N. Ifrah, 2005 .

Long‐term outcome results of the first tandem autotransplant trial for multiple myeloma

J. Crowley, B. Barlogie, J. Shaughnessy, 2006, British journal of haematology.

Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation.

J. Wagner, M. Mohty, P. Dreger, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement

P. Moreau, H. Avet-Loiseau, A. Moreau, 2007, Haematologica.

Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study.

E. Solary, P. Moreau, N. Ifrah, 1996, Blood.

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

P. Sonneveld, A. Nagler, R. Hájek, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin

P. Sonneveld, R. Favis, R. Orlowski, 2010, Annals of Hematology.

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline

D. Esseltine, H. Goldschmidt, P. Wen, 2009, British journal of haematology.

Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations

I. Yakoub-Agha, M. Mohty, P. Moreau, 2010, Haematologica.

Thalidomide in patients with advanced multiple myeloma.

B. Grosbois, I. Yakoub-Agha, S. Leyvraz, 2000, The hematology journal : the official journal of the European Haematology Association.

Autologous hematopoietic stem-cell transplantation for multiple myeloma.

Philippe Moreau, P. Moreau, J. Harousseau, 2009, The New England journal of medicine.

The role of high-dose therapy with autologous stem cell support in the era of novel agents.

J. Harousseau, M. Attal, 2009, Seminars in hematology.

A phase II trial of high-dose imatinib mesylate for relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia: the AFR-15 trial.

P. Chevallier, J. Harousseau, M. Hunault-Berger, 2009, Leukemia research.

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia.

Pierre Fenaux, R. Stone, P. Fenaux, 2007, Blood.

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

M Boccadoro, B. Barlogie, G. Morgan, 2009, Leukemia.

Prognostic significance of copy-number alterations in multiple myeloma.

Cheng Li, Kenneth C. Anderson, Catherine Charbonnel, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

receiving high-dose therapy 2-microglobulin produce a powerful myeloma staging system for patients β Chromosome 13 abnormalities identified by FISH analysis and serum

R. Bataille, J. Mary, P. Moreau, 2013 .

Survival and years of life lost in different age cohorts of patients with multiple myeloma.

B. Barlogie, A. Palumbo, P. Sonneveld, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.

B. Barlogie, M. Dimopoulos, P. Sonneveld, 2009, Blood.

Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia.

E. Solary, B. Vanhaesebroeck, N. Ifrah, 2005, Blood.

Three courses of high dose therapy. Feasibility in the treatment of multiple myeloma–a “France autogreffe” study

P. Colombat, J. Harousseau, C. Linassier, 1994, Cancer.

Single versus double autologous stem-cell transplantation for multiple myeloma.

R. Bataille, R. Bouabdallah, B. Grosbois, 2003, The New England journal of medicine.

Long-term complications of total body irradiation in adults.

P. Moreau, M. Mahé, J. Harousseau, 2001, International journal of radiation oncology, biology, physics.

Factors predicting allogeneic PBSCs yield after G-CSF treatment in healthy donors

P. Chevallier, M. Mohty, P. Moreau, 2009, Bone Marrow Transplantation.

Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients.

D. Blaise, M. Mohty, P. Moreau, 2013, Experimental hematology.

Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma.

J. Bourhis, I. Yakoub-Agha, P. Moreau, 2006, Blood.

Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma.

R. Greil, R. Hájek, B. Paiva, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Haemophagocytic syndrome associated with infections.

J. Harousseau, M. Tiab, F. Mechinaud, 2000, Bailliere's best practice & research. Clinical haematology.

The cancer germ‐line genes MAGE‐1, MAGE‐3 and PRAME are commonly expressed by human myeloma cells

R. Bataille, C. Pellat-deceunynck, G. Jego, 2000, European journal of immunology.

Phase II prospective study of treosulfan-based reduced-intensity conditioning in allogeneic HSCT for hematological malignancies from 10/10 HLA-identical unrelated donor

D. Blaise, M. Mohty, J. Bay, 2012, Annals of Hematology.

Current status of autologous stem cell transplantation for multiple myeloma

M. Mohty, J. Harousseau, F. Malard, 2019, Blood Cancer Journal.

Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update

M. Mohty, A. Bazarbachi, J. Harousseau, 2022, Blood Cancer Journal.

CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis.

R. Bataille, C. Pellat-deceunynck, P. Moreau, 2008, Leukemia research.

A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia

R. Peto, F. Mandelli, R. Gray, 1998, British journal of haematology.

Isolation of human lymphocyte antigens class I-restricted cytotoxic T lymphocytes against autologous myeloma cells.

R. Bataille, C. Pellat-deceunynck, H. Vié, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective

H. Goldschmidt, G. Morgan, M. Dimopoulos, 2010, The oncologist.

Toxicity Profile of Idarubicin: Experiences with Oral and Intravenous Idarubicin in the Treatment of Leukemia

J. Reiffers, J. Harousseau, F. Rigal‐Huguet, 1992 .

Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide/Dexamethasone Who Achieve a Complete or near Complete Response Have Longer Overall Survival and Time to Progression Compared with Patients Achieving a Partial Response.

M. Dimopoulos, J. Zeldis, J. Harousseau, 2007 .

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.

Anthony Boral, Hartmut Goldschmidt, Mario Boccadoro, 2007, Blood.

Erratum: International uniform response criteria for multiple myeloma (Leukemia (2006) vol. 20 (1467-1473) 10.1038/sj.leu.2404284)

B. Barlogie, G. Morgan, M. Dimopoulos, 2006 .

Beyond medicines’ barriers: exploring the true cost of multiple myeloma

D. Hose, P. Keown, J. Harousseau, 2022, Journal of medical economics.

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

M. Dreyling, J. Harousseau, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Bortezomib(Velcade®)-Thalidomide-Dexamethasone (VTD) Is Superior to Thalidomide-Dexamethasone (TD) In Patients with Multiple Myeloma (MM) Progressing or Relapsing After Autologous Transplantation

B. Pégourié, S. Iacobelli, G. Gahrton, 2010 .

VELCADE/Dexamethasone (Vel/D) Versus VAD as Induction Treatment Prior to Autologous Stem Cell Transplantion (ASCT) in Newly Diagnosed Multiple Myeloma (MM): Updated Results of the IFM 2005/01 Trial.

M. Mohty, P. Moreau, G. Marit, 2007 .

Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.

M. Dimopoulos, D. Siegel, J. Zeldis, 2011, Clinical lymphoma, myeloma & leukemia.

The Prognostic Impact of Complete Remission (CR) Plus Very Good Partial Remission (VGPR) in a Double-Transplantation Program for Newly Diagnosed Multiple Myeloma (MM). Combined Results of the IFM 99 Trials.

P. Moreau, H. Avet-Loiseau, T. Facon, 2006 .

elderly multiple myeloma patients ineligible for high-dose therapy Dexamethasone-based regimens versus melphalan-prednisone for

J. Rossi, R. Bataille, I. Yakoub-Agha, 2011 .

Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy

Augustin Ferrant, Chantal Doyen, J. Rossi, 2006 .

High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol.

R. Bouabdallah, H. Tilly, N. Brousse, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.

B. Pégourié, P. Moreau, H. Avet-Loiseau, 2006, Haematologica.

inhibitor tipifarnib in acute myeloid leukemia A 2-gene classifier for predicting response to the farnesyltransferase

Yixin Wang, P. Greenberg, R. Stone, 2008 .

Monoclonal antibodies in the treatment of multiple myeloma

A. Jakubowiak, S. Lonial, P. Richardson, 2011, British journal of haematology.

Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma

D. Esseltine, P. Sonneveld, A. Jakubowiak, 2008, British journal of haematology.

Management of multiple myeloma.

J. Harousseau, 2002, Reviews in clinical and experimental hematology.

CD28, a marker associated with tumoral expansion in multiple myeloma.

Martine, Sophie, R. Bataille, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Study of Lenalidomide Plus Dexamethasone Versus Dexamethasone Alone in Relapsed or Refractory Multiple Myeloma (MM): Results of a Phase 3 Study (MM-010).

Jerome B. Zeldis, M. Dimopoulos, J. Zeldis, 2005 .

The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy.

R. Bataille, M. Amiot, C. Pellat-deceunynck, 2006, Haematologica.

Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup.

H. Dombret, G. Leverger, D. Blaise, 2003, Blood.

Ten years of improvement in the management of multiple myeloma: 2000-2010.

J. Harousseau, 2010, Clinical lymphoma, myeloma & leukemia.

Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies.

P. Chevallier, M. Mohty, P. Moreau, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Prophylaxis with mycophenolate mofetil and CsA can decrease the incidence of severe acute GVHD after antithymocyte globulin-based reduced-intensity preparative regimen and allo-SCT from HLA-matched unrelated donors

P. Chevallier, M. Mohty, P. Moreau, 2010, Bone Marrow Transplantation.

Outcome after reduced-intensity conditioning allogeneic SCT for AML in first complete remission: comparison of two regimens

D. Blaise, M. Mohty, P. Moreau, 2008, Bone Marrow Transplantation.

Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients.

J. Jais, J. Harousseau, F. Guilhot, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High incidence of N and K‐Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis

D Puthier, R. Bataille, M. Devilder, 2001, Human mutation.

Mature B-cell lymphoblastic leukemia with MLL rearrangement: an uncommon and distinct subset of childhood acute leukemia

N. Dastugue, J. Harousseau, P. Talmant, 2008, Leukemia.

Multiple myeloma.

B. Barlogie, J. Shaughnessy, G. Roodman, 2018, Hematology. American Society of Hematology. Education Program.

Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: A report of the french registry on autologous transplantation in multiple myeloma

R. Bataille, J. Bourhis, X. Troussard, 1995, Blood.

The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group

M. Dimopoulos, A. Palumbo, P. Sonneveld, 2010, Leukemia.

Lack of CD27 in myeloma delineates different presentation and outcome

R. Bataille, P. Moreau, H. Avet-Loiseau, 2006, British journal of haematology.

Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study design

David Khayat, Christian Puozzo, D. Khayat, 2004, Cancer Chemotherapy and Pharmacology.

Intermediate-Dose Cytarabine in the Treatment of Relapsed or Refractory Leukemias

J. Harousseau, N. Milpied, 1992 .

Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences.

J. Crowley, B. Barlogie, P. Moreau, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Autologous peripheral blood progenitor cell transplantation for multiple myeloma.

J. Harousseau, M. Attal, 1999, Bailliere's best practice & research. Clinical haematology.

Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma.

R. Bataille, P. Moreau, H. Avet-Loiseau, 2004, Haematologica.

Handbook of Multiple Myeloma

M. Mohty, J. Harousseau, 2015 .

Activity of fludarabine in previously treated Waldenström's macroglobulinemia: a report of 71 cases. Groupe Coopératif Macroglobulinémie.

I. Yakoub-Agha, X. Mariette, P. Morel, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

multiple myeloma autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo followed by a dose-reduced allograft (IFM99-03 trial) with tandem Prospective comparison of autologous stem cell transplantation

G. Marit, J. Harousseau, M. Attal, 2013 .

Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol.

R. Bataille, I. Yakoub-Agha, P. Moreau, 2006, Blood.

A phase II trial of induction and consolidation therapy of acute myeloid leukemia with weekly oral idarubicin alone in poor risk elderly patients

R. Bouabdallah, C. Rose, P. Fenaux, 1999, Leukemia.

Treatment of acute myeloblastic leukemia in adults. The GOELAM experience.

P. Hurteloup, J. Harousseau, Z. Tellier, 1996, Hematology and cell therapy.

Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3‐ITD molecular status for cytogenetically normal AML patients: A GOELAMS study

P. Chevallier, M. Béné, C. Récher, 2012, American journal of hematology.

A white blood cell index as the main prognostic factor in t ( 8 ; 21 ) acute myeloid leukemia ( AML ) : a survey of 161 cases from the French AML Intergroup

H. Dombret, G. Leverger, D. Blaise, 2002 .

Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin

P. Chevallier, D. Blaise, M. Mohty, 2010, Leukemia.

Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS.

M. Béné, J. Reiffers, C. Récher, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Enzastaurin in Previously Treated Waldenstrom's Macroglobulinemia: An Open-Label, Multicenter, Phase II Study.

S. Treon, I. Ghobrial, V. Leblond, 2009 .

Lung Resection for Invasive Pulmonary Aspergillosis in Neutropenic Patients with Hematologic Malignancies: Long Term Results in Thirty Two Cases.

P. Moreau, C. Touzeau, J. Delaunay, 2006 .

Zoledronate Is a Potent Inhibitor of Myeloma Cell Growth and Secretion of IL‐6 and MMP‐1 by the Tumoral Environment

R. Bataille, M. Amiot, P. Berthaud, 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma

P. Chevallier, M. Mohty, P. Moreau, 2010, Leukemia & lymphoma.

A Multicenter Randomized Comparison of Maintenance Treatment with Androgens in Elderly Acute Myeloid Leukemia after ICL Regimen as Induction Therapy: Results of the Goelams-2002 Study.

M. Béné, C. Récher, F. Bauduer, 2006 .

[Allogenic bone marrow grafts in acute myeloid leukemias. A retrospective study in 111 grafted patients in first complete remission].

V. Leblond-Missenard, E. Gluckman, J. Harousseau, 1986, Presse medicale.

Autologous transplantation for multiple myeloma.

J. Harousseau, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Improved Outcome with Androgens as Maintenance Treatment in Elderly Patients with Acute Myeloid Leukemia after ICL Regimen as Induction Therapy: Results of the GOELAMS SA-2002 Multicenter Phase III Randomized Open Trial

M. Béné, C. Récher, F. Bauduer, 2008 .

Gentuzumab-Ozogamicin (GO) Plus Idarubicin (I) and Cytarabine (C) as Induction Treatment for Elderly Patients with Poor-Risk Cytogenetics Acute Myeloid Leukemia (AML).

C. Récher, N. Ifrah, N. Vey, 2007 .

Successful treatment of adult acute lymphoblastic leukemia after relapse with prednisone, intermediate‐dose cytarabine, mitoxantrone, and etoposide (PAME) chemotherapy

C. Gisselbrecht, C. Sebban, X. Troussard, 1990, Cancer.

Mitoxantrone and intermediate-dose cytarabine in relapsed or refractory acute myeloblastic leukemia.

J. Harousseau, N. Milpied, J. Brière, 1990, Nouvelle revue francaise d'hematologie.

Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma.

I. Yakoub-Agha, M. Mohty, S. Leyvraz, 2008, Blood.

Ovarian transposition by laparoscopy before radiotherapy in the treatment of hodgkin's disease

P. Moreau, M. Mahé, J. Harousseau, 1998, Cancer.

High-dose therapy in multiple myeloma.

J. Harousseau, M. Attal, 2002, The hematology journal : the official journal of the European Haematology Association.

Comprehensive Review of AL amyloidosis: some practical recommendations

M. Mohty, A. Bazarbachi, J. Harousseau, 2021, Blood Cancer Journal.

melphalan-prednisone versus melphalan-prednisone analysis of the phase 3 VISTA study of bortezomib plus therapy: diagnosed multiple myeloma patients treated with nonintensive Superior outcomes associated with complete response in newly

D. Esseltine, A. Palumbo, J. Miguel, 2012 .

Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up.

M. Dreyling, J. Harousseau, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Preliminary Results of an IFM Phase II Study

J. Harousseau, V. Coiteux, M. Attal, 2005 .

Recent Advances of Thalidomide in the Treatment of Multiple Myeloma

J. Harousseau, 2008 .

Impact of prior thalidomide (T) therapy on the efficacy of pegylated liposomal doxorubicin (PLD) and bortezomib (B) in relapsed/refractory multiple myeloma (RRMM)

P. Sonneveld, A. Nagler, R. Hájek, 2007 .

Major Superiority of Melphalan - Prednisone (MP) + Thalidomide (THAL) over MP and Autologous Stem Cell Transplantation in the Treatment of Newly Diagnosed Elderly Patients with Multiple Myeloma.

Brigitte Pegourie, J. Y. Mary, B. Pégourié, 2005 .

Maintenance therapy in multiple myeloma

J. Harousseau, 2009, Hematology Reviews.

Persistence of CD33 expression at relapse in CD33+ acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease

P. Chevallier, M. Mohty, H. Avet-Loiseau, 2008, British journal of haematology.

Treatment of Multiple Myeloma Patients Who Have Received at Least One Prior Therapy

J. Harousseau, 2007 .

High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation (auto-SCT) Versus CHOP Regimen in Patients with Untreated Aggressive Non-Hodgkin’s Lymphoma: An Update of the GOELAMS 072 Trial with a Median Follow-up of 9.8 Years

J. Rossi, R. Gressin, E. Deconinck, 2008 .

Daratumumab in transplant regimens for myeloma?

M. Mohty, J. Harousseau, 2020, Blood.

Hierarchical Evaluation of Baseline Poor-Prognosis Factors and Response to Initial Therapy in Younger Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL) Treated in the Risk-Adapted GRAALL-2003 Study.

H. Dombret, E. Macintyre, A. Delannoy, 2005 .

Thalidomide in multiple myeloma: past, present and future.

J. Harousseau, 2006, Future oncology.

Bortezomib, Thalidomide, and Dexamethasone (VTD) Versus VTD Plus Cyclophosphamide as Induction Therapy in Previously Untreated Multiple Myeloma Patients Eligible for HDT-ASCT: A Randomized Phase 2 Trial.

R. Greil, R. Hájek, H. Ludwig, 2009 .

Overexpression of Her2/neu is observed in one third of adult acute lymphoblastic leukemia patients and is associated with chemoresistance in these patients.

P. Chevallier, H. Avet-Loiseau, J. Harousseau, 2004, Haematologica.

Multiple myeloma.

P. L. Bergsagel, W. Kuehl, W. Dalton, 2001, Hematology. American Society of Hematology. Education Program.

Intensive short term therapy with granulocyte-macrophage-colony stimulating factor support, similar to therapy for acute myeloblastic leukemia, does not improve overall results for adults with acute lymphoblastic leukemia. GOELAMS Group.

N. Ifrah, J. Harousseau, C. Linassier, 1999, Cancer.

Maintenance Treatment with Thalidomide after Autologous Transplantation for Myeloma : First Analysis of a Prospective Randomized Study of the Intergroupe Francophone du Myelome (IFM 99 02).

B. Coiffier, J. Bourhis, S. Leyvraz, 2004 .

Long-term follow-up of autotransplant (AT)-supported high-dose melphalan (hdm) for multiple myeloma (MM): Update of Intergroup Francophone du Myelome (IFM), Southwest Oncology Group (SWOG), and Arkansas (ARK) Total Therapy (TT) trials.

J. Crowley, B. Barlogie, J. Harousseau, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of Molecular Predictors of Response in a Study of Tipifarnib Treatment in Relapsed and Refractory Acute Myelogenous Leukemia

David C. Atkins, Bob Löwenberg, David Atkins, 2007, Clinical Cancer Research.

Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation.

R. Bataille, M. Amiot, J. Harousseau, 1999, Journal of immunology.

Reduced-intensity conditioning for allogeneic stem cell transplantation: 10 years later

P. Chevallier, A. Nagler, M. Mohty, 2009, Current opinion in oncology.

Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death.

H. Goldschmidt, A. Palumbo, P. Sonneveld, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multiple Myeloma - a New Era of Treatment Strategies

G. Tonon, S. Lonial, D. Ribatti, 2012 .

Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countries.

J. Harousseau, B. Durie, V. Hungria, 2019, Clinical lymphoma, myeloma & leukemia.

[Treatment of febrile episodes in neutropenic children by ceftazidime combined with netilmicin. Results of a multicenter study apropos of 88 cases].

G. Leverger, O. Taboureau, P. Reinert, 1987, Pathologie et biologie.

CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity.

R. Bataille, P. Moreau, H. Avet-Loiseau, 2005, Haematologica.

Rituximab in CD20 positive multiple myeloma

R. Bataille, C. Dumontet, P. Moreau, 2007, Leukemia.

Treatment of low‐grade non‐Hodgkin's lymphomas: Assessment of doxorubicin in a controlled trial

B. Coiffier, C. Gisselbrecht, M. Boiron, 1990, Hematological oncology.

The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib.

J. Armand, J. Drach, J. S. San Miguel, 2007, The oncologist.

Reply to K. Filanovsky et al

P. Chevallier, M. Mohty, H. Avet-Loiseau, 2010 .

t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma

P. Moreau, H. Avet-Loiseau, J. Harousseau, 2003, Leukemia.

A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma

P. Moreau, X. Leleu, T. Robak, 2010 .

Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma.

M. Dimopoulos, P. Sonneveld, J. S. San Miguel, 2009, Blood reviews.

Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed myeloma

P. Sonneveld, K. Anderson, S. Lonial, 2005 .

Localized invasive pulmonary aspergillosis in patients with neutropenia. Effectiveness of surgical resection

P. Moreau, J. Zahar, B. Mahé, 1993, Cancer.

Bortezomib vs. dexamethasone in relapsed multiple myeloma: A phase 3 randomized study.

P. Sonneveld, P. Richardson, W. Dalton, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multicentre study of a randomized therapeutic protocol in previously untreated patients with Ph-positive chronic myelogenous leukaemia: interferon alfa-2b and hydroxyurea with or without cytosine arabinoside , preliminary results.

H. Tilly, J. Tanzer, F. Bauters, 1991, European journal of cancer.

Collagen gel cultures for detection of spared hematopoietic progenitors in Asta Z 7557 purged human marrows.

I. Dobo, V. Praloran, M. Naud, 1990, Leukemia.

New treatments in multiple myeloma: beyond optimal treatment.

J. Harousseau, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Has the Prognostic of Primary Plasma Cell Leukemia Improved with New drugs

P. Moreau, X. Leleu, J. Harousseau, 2009 .

Frequency, Characteristics, and Reversibility of Peripheral Neuropathy (PN) in the APEX Trial.

H. Goldschmidt, P. Sonneveld, K. Anderson, 2005 .

Bortezomib (VELCADE®) Plus Dexamethasone as Induction Treatment Prior to Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: Preliminary Results of an IFM Phase II Study.

R. Gressin, X. Leleu, J. Harousseau, 2004 .

[Hemophagocytic syndromes. A series of 23 cases].

F. Raffi, J. Harousseau, M. Hamidou, 1996, Annales de medecine interne.

Intensive therapy in multiple myeloma.

J. Harousseau, 1999, Pathologie et biologie.

Development of genomic markers that predict response to molecularly targeted antileukemic therapy.

M. Raponi, J. Harousseau, 2008, Expert opinion on medical diagnostics.

Remission induction and maintenance modalities in acute myeloid leukemia: a multicenter randomized study.

G. Leverger, M. Marty, M. Boiron, 1987, Haematology and blood transfusion.

Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience.

B. Pégourié, O. Decaux, P. Moreau, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients

P. Moreau, F. Kraeber-Bodéré, J. Barbet, 2012, Tumor Biology.

Impact of Chromosomal Abnormalities Del(13), T(4;14), and Del(17p) and Prior Treatment on Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Treated with Lenalidomide

J. Soulier, P. Moreau, T. Facon, 2008 .

Elotuzumab In Combination with Lenalidomide and Low-Dose Dexamethasone In Patients with Relapsed/Refractory Multiple Myeloma: Interim Results of a Phase 1 Study

S. Jagannath, S. Lonial, R. Vij, 2010 .

Two cases of acute lymphoblastic leukaemia following acute myeloid leukaemia.

P. Chevallier, J. Harousseau, P. Talmant, 2008, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

Superior Outcomes Associated with Complete Response: Analysis of the Phase III VISTA Study of Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone

M. Dimopoulos, A. Palumbo, J. Miguel, 2008 .

A Phase I Study of Vorinostat, Lenalidomide, and Dexamethasone In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Excellent Tolerability and Promising Activity In a Heavily Pretreated Population

M. Dimopoulos, D. Siegel, P. Richardson, 2010 .

Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM).

M. Dimopoulos, K. Anderson, D. Siegel, 2010 .

Intermediate-risk childhood acute lymphoblastic leukemias: amsacrine + cytosine arabinoside versus intermediate-dose methotrexate for consolidation, and 6-mercaptopurine + methotrexate + vincristine versus monthly pulses for maintenance.

G. Leverger, C. Griscelli, S. Lemerle, 1987, Haematology and blood transfusion.

Application of the study of prognostic factors to the treatment of childhood (less than 20 years old) acute lymphoblastic leukemia.

C. Griscelli, M. Weil, F. Bauters, 1980, Bulletin du cancer.

International uniform response criteria for multiple myeloma

B. Barlogie, G. Morgan, M. Dimopoulos, 2007, Leukemia.

Lenalidomide After Autologous Transplantation for Myeloma: First Analysis of a Prospective, Randomized Study of the Intergroupe Francophone Du Myelome (IFM 2005 02).

S. Leyvraz, P. Moreau, H. Avet-Loiseau, 2009 .

Genetic variation associated with bortezomib-induced peripheral neuropathy

G. Mulligan, P. Richardson, R. Favis, 2011, Pharmacogenetics and genomics.

Up-front ixazomib in older patients with myeloma.

M. Mohty, J. Harousseau, 2021, Blood.

Phase 1/2 Study of Elotuzumab in Combination with Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma: Interim Results.

S. Jagannath, S. Lonial, R. Vij, 2009 .

Identification of Molecular Predictors of Response to ZARNESTRA™ (Tipifarnib, R115777) in Relapsed and Refractory Acute Myeloid Leukemia.

David C. Atkins, Yixin Wang, Yi Zhang, 2004 .

Metalloproteinase-2 Activation Its Potential Involvement in ( Matrilysin ) by Human Myeloma Cells and Production of Metalloproteinase-7

R. Bataille, J. Harousseau, S. Barillé, 1999 .

Bortezomib Demonstrates Superior Efficacy to High-Dose Dexamethasone in Relapsed Multiple Myeloma: Final Report of the APEX Study.

H. Goldschmidt, P. Sonneveld, S. Lonial, 2004 .

Frontline Therapy with Bortezomib, Lenalidomide, and Dexamethasone (VRD) Induction Followed by Autologous Stem Cell Transplantation, VRD Consolidation and Lenalidomide Maintenance In Newly Diagnosed Multiple Myeloma Patients: Primary Results of the IFM 2008 Phase II Study

B. Pégourié, P. Moreau, H. Avet-Loiseau, 2010 .

[Treatment of localized forms of Hodgkin's disease with 3 courses of chemotherapy (ABVD-MP) in combination with wide focal and prophylactic lumbo-splenic radiotherapy. The POF 81/12 protocol].

N. Ifrah, J. Harousseau, F. Guilhot, 1989, Presse medicale.

Interferon α extends the survival of human myeloma cells through an upregulation of the Mcl‐1 anti‐apoptotic molecule

R. Bataille, M. Amiot, D. Puthier, 2001, British journal of haematology.

Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma

R. Neuwirth, P. Sonneveld, P. Richardson, 2009, British journal of haematology.

Multiple myeloma.

R. Bataille, J. Shaughnessy, J. Harousseau, 1997, The New England journal of medicine.

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

P. Sonneveld, A. Nagler, R. Hájek, 2008, Cancer.

Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies

H. Goldschmidt, P. Sonneveld, J. Miguel, 2012 .

Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome.

P. Sonneveld, A. Nagler, R. Hájek, 2011, Clinical lymphoma, myeloma & leukemia.

Probable disseminated cerebral aspergillosis: recovery with medical treatment.

H. Avet-Loiseau, J. Harousseau, F. Méchinaud-Lacroix, 1994, Nouvelle revue francaise d'hematologie.

Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).

B. Grosbois, I. Yakoub-Agha, A. Duhamel, 2002, The hematology journal : the official journal of the European Haematology Association.

Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin’s lymphoma by 18F-fluorodeoxyglucose positron emission tomography

D. Huglo, B. Dupas, C. Bodet-Milin, 2008, Haematologica.

CD130 rather than CD126 expression is associated with disease activity in multiple myeloma

Philippe Moreau, R. Bataille, M. Amiot, 1999, British journal of haematology.

A pilot study of 220 mg/m2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: pharmacokinetics and toxicity

R. Bataille, P. Moreau, B. Mahé, 1996, British journal of haematology.

Comparison of Outcomes After Unrelated Cord Blood Transplantation and Matched Unrelated Donor RIC Transplantation for Lymphoid Malignancies - A Eurocord-Netcord Group/ Lymphoma Working Party and Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation Study.

J. Wagner, J. Finke, D. Blaise, 2009 .

Multiple myeloma.

J. Shaughnessy, J. Harousseau, P. Richardson, 2004, Hematology. American Society of Hematology. Education Program.

Requirements for operational cure in multiple myeloma.

M. Mohty, H. Avet-Loiseau, J. Harousseau, 2021, Blood.

Inhibiting IL-6 in human multiple myeloma.

B. Klein, R. Bataille, J. Harousseau, 1992, Current topics in microbiology and immunology.

Cerebrospinal fluid neopterin levels in children with central nervous system leukemia.

F. Bauters, J. Harousseau, F. Millot, 1993, Leukemia and Lymphoma.

Genetic Associations with Bortezomib Mediated Neuropathy in Multiple Myeloma.

H. Goldschmidt, G. Morgan, P. Sonneveld, 2009 .

Analysis of Cost-Effectiveness Assessments In France By The French National Authority For Health (Has).

J. Harousseau, C. Rumeau-Pichon, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Early intensive therapy with autotransplantation for high-risk Hodgkin's disease.

P. Moreau, B. Dupas, B. Mahé, 1993, Leukemia & lymphoma.

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.

A. Hagenbeek, B. Coiffier, P. Sonneveld, 1995, The New England journal of medicine.

A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup.

H. Dombret, G. Leverger, D. Blaise, 2002, Blood.

[Course of refractory anemias. Study of 49 cases].

N. Gorin, J. Harousseau, A. Najman, 1974, Annales de medecine interne.

110 cases from the French AML Intergroup Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of

G. Leverger, D. Blaise, J. Reiffers, 2013 .

Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival : an analysis of 10 549 patients from the International Myeloma Working Group

B. Barlogie, M. Dimopoulos, P. Sonneveld, 2008 .

Bone marrow transplantation for adult poor prognosis lymphoblastic lymphoma in first complete remission

D. Blaise, N. Ifrah, P. Colombat, 1989, British journal of haematology.

Prospective comparison of autologous stem cell transplantation followed by a dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple

I. Yakoub-Agha, G. Marit, J. Harousseau, 2005 .

Current status of autologous stem cell transplantation for multiple myeloma

M. Mohty, J. Harousseau, F. Malard, 2019, Blood Cancer Journal.

Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).

P. Hurteloup, J. Abgrall, P. Hervé, 1997, Blood.

Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols.

P. Cony-Makhoul, C. Patte, A. Delmer, 1995, Blood.

Current Advances in Multiple Myeloma: A Post International Myeloma Society (IMS 2022) Round Table Debate by the International Academy for Clinical Hematology (IACH)

C. Touzeau, T. Facon, J. Harousseau, 2023, Clinical Hematology International.

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Monosomy 13 Is Associated With the Transition of Monoclonal Gammopathy of Undetermined Signiﬁcance to Multiple Myeloma

R. Bataille, B. Grosbois, Jian-yong Li, 2022 .

Evolution of Antithrombin (AT) and Fibrinogen (Fg) Levels during Induction Chemotherapy with L-Asparaginase (Asp) in Adult Patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL). Clinical Outcomes and Use of Coagulation Supportive Treatments: The CAPELAL Study.

M. Bernard, Y. Gruel, N. Ifrah, 2004 .

Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients

B. Coiffier, B. Grosbois, C. Sebban, 2003, Leukemia.

Efficacy of FDG-PET/CT Imaging To Guide Biopsies in the Detection of Richter’s Syndrome.

P. Moreau, A. Moreau, B. Dupas, 2007 .

Primary Epstein-Barr virus infection with clonal T-cell lymphoproliferation.

V. Praloran, A. Moreau, M. Fiche, 1992, American journal of clinical pathology.

Double intensive consolidation chemotherapy in adult acute myeloid leukemia.

N. Ifrah, J. Harousseau, N. Milpied, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hb Saint Nazaire (β103[G5]Phe→Ile): A new example of polycythemia due to a hemoglobin variant with increased oxygen affinity

H. Wajcman, J. Kister, F. Galactéros, 1993 .

J. Bourhis, I. Yakoub-Agha, P. Moreau, 2006, Blood.

Fluorescence in situ hybridization on peripheral-blood specimens is a reliable method to evaluate cytogenetic response in chronic myeloid leukemia.

R. Bataille, P. Moreau, J. Harousseau, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radioimmunotherapy in non-Hodgkin's lymphoma (NHL) using a fractionated schedule of DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.

C. Kirsch, R. Naumann, J. Chatal, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Can peripheral T-cell lymphomas be morphologically subclassified? A morphometric approach to 21 cases.

P. Gaulard, F. Sigaux, G. Flandrin, 1986, Cytometry.

Management of Multiple Myeloma with Bortezomib: Experts Review the Data and Debate the Issues

P. Sonneveld, M. Boccadoro, J. Cavenagh, 2007, Oncology.

IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.

T. Haferlach, S. Schnittger, W. Kern, 2010, Blood.

Clinical Trials and Observations

C. Bloomfield, L. Staudt, A. Rosenwald, 2005 .

Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy.

B. Pégourié, B. Grosbois, J. Mary, 2006, Blood.

Interest of Non-Myeloablative Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma: A Multicenter Retrospective Study.

I. Yakoub-Agha, A. Nagler, M. Mohty, 2008 .

A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup.

H. Dombret, G. Leverger, D. Blaise, 2002, Blood.

Bortezomib in Combination with High-Dose Dexamethasone (HD dex) and Erythropoietin (EPO) Does Not Result in an Increased Risk of Thromboembolic Complications.

D. Esseltine, P. Sonneveld, S. Jagannath, 2006 .

The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group

M. Dimopoulos, P. Sonneveld, A. Chanan-Khan, 2010, Leukemia.

Erratum: Myeloma management guidelines: A consensus report from the scientific advisors of the international myeloma foundation (The Hematology Journal (2003) vol, 4 (379-398) 10.1038/sj.thj.6200312)

G. Morgan, P. Sonneveld, J. Miguel, 2004 .

Candidemia in patients with hematologic malignancies: analysis of 7 years' experience in a single center.

J. Harousseau, S. Vigouroux, NoE¨l Milpied, 2006, Haematologica.

Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study.

G. Salles, P. Moreau, X. Leleu, 2009, Blood.

Vinorelbine (VRL) in patients with recurrent multiple myeloma (MM): A phase II study

T. Facon, J. Harousseau, F. Maloisel, 1997 .

R. Houot, L. Fornecker, R. Gressin, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma.

P. Moreau, J. Harousseau, N. Milpied, 2005, Haematologica.

Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.

R. Neuwirth, H. Goldschmidt, P. Sonneveld, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease.

R. Porcher, A. Stamatoullas, E. Deconinck, 2001, Blood.

Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients.

P. Moreau, J. Harousseau, N. Milpied, 1992, The Journal of antimicrobial chemotherapy.

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.

W. Jędrzejczak, H. Dombret, G. Martinelli, 2007, Blood.

P. Moreau, H. Avet-Loiseau, G. Marit, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HIGH DOSE MELPHALAN AND AUTOLOGOUS BONE MARROW TRANSPLANTATION IN HIGH RISK MYELOMA

J. Bourhis, J. Harousseau, N. Milpied, 1987, British journal of haematology.

Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients

M. Mohty, P. Moreau, A. Moreau, 2011, Bone Marrow Transplantation.

High-grade B-cell lymphoma/leukemia associated with t(14;18) and 8q24/MYC rearrangement: a neoplasm of germinal center immunophenotype with poor prognosis

R. Zini, S. Molica, L. Medeiros, 2007, Haematologica.

Early intensive therapy with autologous stem cell transplantation in advanced Hodgkin’s disease: retrospective analysis of 158 cases from the French registry

R. Bouabdallah, O. Casasnovas, C. Gisselbrecht, 1998, Bone Marrow Transplantation.

Individualizing treatment of patients with myeloma in the era of novel agents.

J. Harousseau, J. San-Miguel, D. Joshua, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I study of AMGN‐0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases

A. Nakanishi, X. Mariette, P. Greipp, 2003, Cancer.

Gamma groceries.

P. Hervé, J. Harousseau, T. Philip, 1998, Environmental health perspectives.

Late Complications and Quality of Life after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation.

P. Chevallier, M. Mohty, P. Moreau, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

M. Mohty, P. Moreau, H. Avet-Loiseau, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Candidemia in patients with hematologic malignancies: analysis of 7 years' experience in a single center.

J. Harousseau, S. Vigouroux, NoE¨l Milpied, 2006, Haematologica.

Clonal Hematologic Disorders in Down Syndrome A Review

J. Harousseau, H. Avet‐Loiseau, F. Méchinaud, 1995, Journal of pediatric hematology/oncology.

Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis.

M. Mohty, J. Harousseau, F. Malard, 2017, Cancer treatment reviews.

Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group.

B. Barlogie, P. Sonneveld, M. Boccadoro, 2008, Blood.

Clinical management of myeloma--state of the art.

J. Harousseau, 2010, Cancer treatment reviews.

Optimising patient outcomes in myeloma.

J. Harousseau, 2010, Cancer treatment reviews.

Survival and years of life lost in different age cohorts of patients with multiple myeloma.

B. Barlogie, A. Palumbo, P. Sonneveld, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy : analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone

D. Esseltine, M. Dimopoulos, A. Palumbo, 2010 .

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma: A phase I study.

D. Siegel, P. Richardson, C. Mitsiades, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reduced Intensity Allogeneic Stem Cell Transplantation for Follicular Lymphoma Results in An Improved Progression Free Survival When Compared to Autologous Stem Cell Transplantation. An Analysis from the Lymphoma Working Party of the EBMT

R. Foà, H. Tilly, D. Blaise, 2008 .